Gan & Lee Pharmaceuticals(603087) 3 on March 10, it was announced that gzr18 independently developed by the company was conducting phase I clinical trial in the United States, and the first subject was successfully enrolled in the group recently.
According to the introduction, GZR18 is a glucagon like peptide -1 (GLP-1) receptor agonist injected once a week. This clinical trial aims to develop indications for type 2 diabetes. GLP-1 regulates the secretion of glucocorticoids, promotes insulin secretion and inhibits glucagon release in a Glucose dependent manner, which is impaired in type 2 diabetes. Compared with insulin injections, GLP-1 receptor agonists (glp-1ra) can reduce the incidence of hypoglycemia compared with insulin injections because GLP-1 promotes insulin secretion in a glucose concentration dependent manner.
Gzr18 was approved by FDA of the US Food and drug administration to carry out phase I clinical trial in December 2021. The company will mainly investigate the safety and tolerance of gzr18 in healthy subjects through double-blind, randomized, placebo-controlled, sequential and single incremental dose clinical phase I trial, and the secondary objective is to evaluate the pharmacokinetic (PK) parameters of gzr18 in healthy subjects. The drug research is progressing smoothly, and the first subject has been successfully enrolled in the group recently.
According to the announcement, as of September 30, 2021, Gan & Lee Pharmaceuticals(603087) has invested 58.12 million yuan of R & D expenses in the project.
